Treatment sequencing in advanced ALK-positive NSCLC

Prof. Yinghui Xu, The First Hospital of Jilin University, China
Prof. Hong Yang, Sun Yat-sen University Cancer Center, China
Prof. Sai-Hong Ignatius Ou, School of Medicine, University of California, Irvine, USA
Prof. Xu, Prof. Yang and Prof. Ou discussed treatment sequencing in advanced ALK-positive NSCLC, with particular attention to whether the common strategy of using a second-generation ALK TKI followed by a third-generation agent remains optimal after progression. They also explored the role of repeat biopsy, liquid and tissue-based molecular testing, and how to balance long-term survival with quality of life in post-recurrence management.

Видео Treatment sequencing in advanced ALK-positive NSCLC канала MedJ